NCT03318796Unknown不适用
Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 335
- 试验地点
- 2
- 主要终点
- Target Vessel Failure (TVF)
研究概览
简要总结
TRYTON Post Approval Study (PAS) of the Tryton Side Branch Stent
详细描述
The primary objective of this PAS is to assure the continued safety and effectiveness of the Tryton Side Branch Stent™ with main branch approved DES in the treatment of de novo native coronary artery bifurcation lesions with side branch diameter ranging from ≥2.5 mm to ≤3.5 mm and main branch diameter ranging from ≥2.5 mm to ≤4.0 mm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •General Inclusion Criteria
- •The patient must be ≥18 and ≤ 90 years of age;
- •Acceptable candidate for CABG;
- •The intention to treat the side branch of the target bifurcation based on angiographic evaluation
- •The patient is willing to comply with specified follow-up evaluations;
- •The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided written informed consent, approved by the appropriate Institutional Review Board (IRB).
- •Planned use of FDA approved and commercially available drug-eluting stents (DES) for subject's index procedure Angiographic Inclusion Criteria
- •a) Single de novo lesion in a bifurcation involving both the main branch and the side branch b) The bifurcation: main branch and side branch with a visual diameter stenosis ≥ 50% (Medina classification 1.1.1; 0.1.1; 1.0.1) by visual assessment;
- •Target lesion located in a native coronary artery;
- •a) Bifurcation lesion main branch reference vessel diameter must be ≥2.5 mm to ≤ 4.0 mm, and b) Side branch reference vessel diameter must be ≥2.5mm by visual estimate (≥2.25mm by QCA) and <3.5 mm by visual estimate (<3.25 mm by QCA);
- •a) Bifurcation lesion main branch lesion length ≤ 28 mm and b) Side branch lesion length ≤ 5.0 mm (the ability to be treated with a single stent for both main and side branch);
- •Target lesion ≥50% and <100% stenosed by visual estimate in both the main branch and side branch; -
排除标准
- •General Exclusion Criteria
- •Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test;
- •Impaired renal function (serum creatinine >
- •mg/dL or 150 μmol/l);
- •Platelet count <100,000 cells/mm3 or >700,000 cells/mm3 or a WBC <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis);
- •Presence of a heart transplant
- •Known allergy to cobalt chromium
- •Hypersensitivity or contraindication to cobalt-chromium or structurally-related compounds, cobalt, chromium, nickel, or tungsten
- •Anticipated use of rotational artherectomy
- •Patient in whom the use of a drug eluting stent is contraindicted, e.g., who cannot receive the recommended dual anti-platelet (aspirin and an approved P2Y12 inhibitor) and/or anticoagulant therapy
- •Angiographic Exclusion Criteria:
- •Left main coronary artery disease (protected and unprotected);
- •Trifurcation lesion;
- •Totally occluded target vessels (TIMI flow 0 or 1);
- •Moderate to Severely calcified target lesion(s);
- •Highly calcified target lesion(s) requiring rotational atherectomy;
- •Target lesion has excessive tortuosity unsuitable for stent delivery and deployment;
- •Angiographic evidence of thrombus in the target lesion(s);
- •Tryton Stent placement without angioplasty pre-dilatation of the main branch and side branch (i.e., direct stenting is contraindicated)
- •Tryton Stent placement alone, without implantation of a main branch stent
- •An untreated significant (>50%) stenosis proximal or distal in either the side branch or main branch;
- •Impaired runoff in the treatment vessel with diffuse distal disease;
- •Left ventricular ejection fraction (LVEF) 30% (LVEF must be obtained within 6 months prior to the index procedure); -
研究组 & 干预措施
Interventional
Other
Coronary artery stenting of De novo bifurcation lesions MB & SB
干预措施: Coronary Artery Stenting (Device)
结局指标
主要结局
Target Vessel Failure (TVF)
时间窗: 1 year
Composite of cardiac death, target vessel MI (Q and non-Qwave) clinically driven target vessel revascularization
次要结局
- Lesion success(48 hrs)
- Procedure success(48 hrs)
- Death(1 year)
- Myocardial infarction (MI)(1 year)
- CD-TVR(1 year)
- Stent thrombosis(1 year)
- Device success(48 hrs)
- CD-TLR(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX ArteriesLeft Main Coronary Artery StenosisNCT02765646Tryton Medical, Inc.100
已完成
不适用
Prospective, Single Blind, Rand Controlled Study to Evaluate the Safety & Effectness of Tryton Side Branch Stent Used With DES Treatmt of de Novo Bifurcation Lesions in MB & SB in Native CoronariesCoronary Atherosclerosis of Native Coronary ArteryBifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary ArteryNCT01258972Tryton Medical, Inc.133
已完成
1 期
Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)Angioplasty, Transluminal, Percutaneous CoronaryCoronary Artery DiseaseNCT01174433University of Padova241
已完成
不适用
Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery StenosisStenosisStentsStrokeAtherosclerosisTransient Ischemic AttackNCT00691314Peking Union Medical College Hospital300
已完成
不适用
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery DiseaseCarotid Artery DiseasesNCT05365490Silk Road Medical400